Yahoo
NasdaqGS - Nasdaq Real Time Price USD

IDEXX Laboratories, Inc. (IDXX)

569.69 +6.78 (+1.20%)
As of 10:03:46 AM EDT. Market Open.
Trade IDXX on Coinbase
Chart Range Bar
Loading chart for IDXX

What's happening with IDXX?

17m ago
Powered by Yahoo Scout

IDEXX Laboratories is approaching its November 2, 2026, third-quarter earnings report. Analysts expect continued growth, led by Companion Animal Group diagnostics, software, and laboratory services, while valuation and veterinary-demand risks remain central investor concerns.

Powered by Yahoo Scout
  • Previous Close 562.91
  • Open 570.17
  • Bid 568.54 x 100
  • Ask 501.77 x 100
  • Day's Range 568.01 - 572.56
  • 52 Week Range 500.61 - 769.98
  • Volume 22,256
  • Avg. Volume 545,173
  • Market Cap (intraday) 44.881B
  • Beta (5Y Monthly) 1.55
  • PE Ratio (TTM) 40.07
  • EPS (TTM) 14.23
  • Earnings Date Nov 2, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 694.42
  • Morningstar Rating Rating available with Stock Picks access

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

www.idexx.com

11,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

IDXX
15.72%
S&P 500 (^GSPC)
12.80%

1-Year Return

IDXX
9.16%
S&P 500 (^GSPC)
12.06%

3-Year Return

IDXX
45.68%
S&P 500 (^GSPC)
87.54%

5-Year Return

IDXX
14.41%
S&P 500 (^GSPC)
67.67%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 1.22B
Earnings 338.41M
Profit Margin 27.82%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
800M
1B
1B
23.0%
24.0%
25.0%
26.0%
27.0%

Analyst Insights

View More

Analyst Price Targets

470.00 Low
694.42 Average
569.69 Current
805.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/27/2026
Analyst UBS
Rating Action Maintains
Rating Neutral
Price Action Lowers
Price Target 670 -> 627

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    25.03%

  • Return on Assets (ttm)

    27.09%

  • Return on Equity (ttm)

    74.21%

  • Revenue (ttm)

    4.55B

  • Net Income Avi to Common (ttm)

    1.14B

  • Diluted EPS (ttm)

    14.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    196.93M

  • Total Debt/Equity (mrq)

    67.97%

  • Levered Free Cash Flow (ttm)

    909.37M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: